Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

114P - Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma

Date

14 Sep 2024

Session

Poster session 08

Topics

Cancer Biology;  Genetic and Genomic Testing

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Oscar Gerardo Arrieta Rodriguez

Citation

Annals of Oncology (2024) 35 (suppl_2): S238-S308. 10.1016/annonc/annonc1576

Authors

O.G. Arrieta Rodriguez1, E. Caballe Perez2, N.Y. Hernandez-Pedro3, E. Romero4, J. Lucio-Lozada4, C. Castillo-Ruiz4, K. Acevedo-Castillo5, R.M. Álvarez-Gómez6, C. Molina-Garay5, M. Jiménez-Olivares5, K. Carrillo-Sánchez5, E.C. Mendoza-Caamal5, A.F. Cardona Zorrilla7, J. Remon Masip8, C. Alaez-Verson5

Author affiliations

  • 1 Oncology Department, INCAN - Instituto Nacional de Cancerologia, 14080 - Ciudad de Mexico/MX
  • 2 Medicine Oncology Department, Instituto Nacional de Cancerología, 14080 - Ciudad de Mexico/MX
  • 3 Personalized Medicine Laboratory, Instituto Nacional de Cancerología, 14080 - Ciudad de Mexico/MX
  • 4 Personalized Medicine Laboratory, Instituto Nacional de Cancerología, 14080 - Sección XVI/MX
  • 5 Genomic Diagnosis Laboratory, Instituto Nacional de Medicina Genómica, 14610 - Arenal Tepepan/MX
  • 6 Hereditary Cancer Clinic, Instituto Nacional de Cancerología, 14080 - Ciudad de Mexico/MX
  • 7 Giga/tera Research Group, Luis Carlos Sarmiento Angulo Cancer Treatment And Research Center (ctic)/el Bosque University, CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, 1101031 - Bogota/CO
  • 8 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 114P

Background

Pathogenic or likely pathogenic germline variants (PGVs) in cancer predisposition genes may play a role in lung cancer (LC) susceptibility. However, determining an eligible population for genetic testing remains uncertain. This study aimed to assess the prevalence of PGVs in a selected cohort of individuals with lung adenocarcinoma.

Methods

A cross-sectional cohort study was conducted to assess PGVs rate in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic alterations (AGAs). Sequencing was performed using Sophia Hereditary Cancer Solution panel F, including 144 cancer predisposition genes. Variants classified as pathogenic or likely pathogenic were included for further analysis.

Results

We incluided 201 patients, of which 43 (21.4%) exhibited PGVs, identifying that 64.5% occurred in DNA damage repair genes, being 86.1% clinically actionable. The most frequent PGVs were found in ATM (9.3%), TP53 (6.9%), BRCA2 (6.9%), and CHEK2 (6.9%) genes. PGVs were associated with male sex (adjusted odds ratio [aOR] 2.54, 95% CI 1.17–5.53, p=0.019), very young-onset presentation (aOR 5.79, 95% CI 1.35–24.74, p=0.018), and first-degree relatives with LC (aOR 3.78, 95% CI 1.11–12.83, p=0.033), along with a trend toward association with AGAs (aOR 6.42, 95% CI 0.79–52.18, p=0.082).

Conclusions

This study identified a high PGVs prevalence based on our selection criteria, thus representing an effective strategy to select candidates for germline genomic testing, potential screening strategies in close relatives, and personalized therapeutic modalities. Our results warrant further exploration in other populations to confirm them.

Clinical trial identification

NCT06181812.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study was supported by CONAHCyT (A3-S-47960) and Becas Impulso a La Investigación En Salud “Carlos Slim” 2023 (N20230149).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.